Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28108700 | 0.88 | PPARA (0.42) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL17164338 | 0.86 | MAPT (0.43) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL17164357 | 0.85 | CHRNB4 (0.37) | MAPTLMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL21854579 | 0.84 | MAPT (0.37) | MAPTLMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL17164367 | 0.84 | S1PR4 (0.38) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL20521342 | 0.82 | MEN1 (0.39) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL20521343 | 0.82 | MEN1 (0.39) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL18703334 | 0.81 | MAPT (0.43) | MAPTLMNAMEN1KMT2ANPC1 | |
| SCHEMBL20521493 | 0.81 | MAPT (0.37) | MAPTLMNANPC1ALDH1A1 | |
| SCHEMBL20448215 | 0.79 | MAPT (0.38) | MAPTLMNAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-25 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| US-20200347079-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-05 | — | — | US | disclosed |
| US-20200123174-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-23 | — | — | US | disclosed |
| EP-3601236-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-3601253-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018177899-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018177889-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MAPT 4662/4885LMNA 2531/4885MEN1 647/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | MAPT 4687/4885LMNA 3066/4885MEN1 803/4885 |
| US-20200347079-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | MAPT 4687/4885LMNA 3066/4885MEN1 803/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MAPT 4662/4885LMNA 2531/4885MEN1 647/4885 |
| US-20200123174-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | MAPT 4687/4885LMNA 3066/4885MEN1 803/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | MAPT 4662/4885LMNA 2531/4885MEN1 647/4885 |
| US-20220267353-A1 | PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PPIB, RHEB | MAPT 4662/4885LMNA 2531/4885MEN1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.